"We are proud to announce these filings for the use of our RSV vaccine candidate, mRNA-1345, in the
"RSV is a major cause of lower respiratory tract infections in older adults and can cause a significant burden to health systems through hospitalizations and emergency care admissions,"
According to the company, the vaccine was well-tolerated, with a favorable safety profile.
"Most solicited adverse reactions were mild or moderate, and the most commonly reported solicited adverse reactions in the mRNA-1345 group were injection site pain, fatigue, headache, myalgia and arthralgia,"
The
The company has more vaccines in the pipeline, including Phase 3 trials to protect against the flu and a next-generation COVID-19 vaccine candidate.
Copyright 2023 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source